The Exchange has sought clarification from Syngene International Limited with respect to recent news item captioned Syngene expands Biologics facility with new ADC bioconjugation capability. The response from the Company is awaited.
SYNGENE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The NSE has asked Syngene International to clarify a recent news report about the company adding new ADC (Antibody-Drug Conjugate) bioconjugation capability to its Biologics facility. The company has not yet responded, and its reply is awaited. ADC bioconjugation is a specialised technology used in cancer drug development, and this expansion would enhance Syngene's Biologics service offerings. Such exchange clarifications are routine and triggered when significant corporate news appears in the media.
No direct impact on shareholders; this is a standard exchange query pending the company's response on a positive capacity expansion announcement. Investors should await the company's clarification for confirmation of the news.